U.S. Stock Market Movement | Latigo Biotherapeutics (LTGO.US) Debuts on U.S. Market, Shares Surge Over 14% After Opening

智通财经2026/08/07 16:36

Show original

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Zhituo Finance APP has learned that on Friday, non-opioid painkiller developer Latigo Biotherapeutics (LTGO.US) debuted on the US stock market. As of press time, the stock had risen over 14%, trading at $20.53. Latigo is dedicated to developing non-opioid analgesics targeting the Nav1.8 sodium ion channel. Its core candidate drug, LTG-001, is an oral Nav1.8 inhibitor mainly used to treat moderate to severe acute pain, including postoperative pain. This medication aims to provide pain relief comparable to opioids while avoiding the risk of addiction. Nav1.8 is primarily expressed in peripheral pain-sensing neurons, and its inhibitor does not act on the central nervous system, thus eliminating addictive potential.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

The most important data release next week will be the U.S. July CPI report on Wednesday, followed by the PPI data on Thursday. Deutsche Bank's U.S. economists expect the headline consumer price index to rise 0.15% month-on-month, compared to a 0.42% decline in June; the core CPI is expected to increase 0.26% month-on-month, the same as in June. As for the PPI data, the overall PPI is expected to rise 0.22% month-on-month (previously 0.13%).

智通财经•2026/08/08 03:21

Data center operator Switch has secretly filed for a U.S. IPO, could be listed as early as November

智通财经•2026/08/08 02:46